
Nathan J Robison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1731617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
2	Diffuse intrinsic pontine glioma: a reassessment. Journal of Neuro-Oncology, 2014, 119, 7-15.	2.9	99
3	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	7.0	92
4	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
5	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-Oncology, 2016, 18, 126-131.	1.2	69
6	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology, 2021, 39, 797-806.	1.6	54
7	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-Oncology, 2020, 22, 1527-1535.	1.2	45
8	Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget, 2019, 10, 551-557.	1.8	44
9	Allergic reactions and antiasparaginase antibodies in children with highâ€risk acute lymphoblastic leukemia: A children's oncology group report. Cancer, 2015, 121, 4205-4211.	4.1	28
10	Unusual radiological and histological presentation of a diffuse leptomeningeal glioneuronal tumor (DLGNT) in a 13-year-old girl. Child's Nervous System, 2019, 35, 1609-1614.	1.1	20
11	Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. Journal of Neurosurgery: Pediatrics, 2017, 20, 51-55.	1.3	19
12	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro-Oncology, 2020, 22, 1696-1704.	1.2	14
13	A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children's Oncology Group. Journal of Neuro-Oncology, 2018, 140, 575-582.	2.9	9
14	Clinical and neuropsychological outcome of pediatric nonâ€midline central nervous system germinoma treated with chemotherapy and reduced dose/volume irradiation: The Children's Hospital Los Angeles experience. Pediatric Blood and Cancer, 2019, 66, e27983.	1.5	9
15	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1â€associated optic pathway gliomas in children. Pediatric Blood and Cancer, 2021, 68, e28833.	1.5	9
16	Cerebral sinus thrombosis in a child with active ulcerative colitis and factor V Leiden. Pediatric Blood and Cancer, 2009, 52, 867-869.	1.5	7
17	Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. Journal of Neuro-Oncology, 2018, 138, 199-207.	2.9	7
18	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. Journal of Neuro-Oncology, 2019, 145, 375-383.	2.9	7

NATHAN J ROBISON

#	Article	IF	CITATIONS
19	DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro-Oncology, 2022, 24, i19-i20.	1.2	4
20	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. Neuro-Oncology Advances, 2021, 3, vdab037.	0.7	3
21	Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients. Journal of Pediatric Hematology/Oncology, 2021, 43, e1201-e1204.	0.6	1
22	MEDB-86. A re-induction regimen for children with recurrent medulloblastoma. Neuro-Oncology, 2022, 24, i126-i127.	1.2	1
23	AT-23ENCOURAGING SURVIVAL OF PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID AND RHABDOID TUMOR (AT/RT) TREATED AS PER CHILDREN'S ONCOLOGY GROUP ACNS0333 STUDY: A SINGLE-INSTITUTION EXPERIENCE. Neuro-Oncology, 2016, 18, iii6.3-iii6.	1.2	0
24	Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961 Blood, 2009, 114, 3077-3077.	1.4	0
25	Cardiac Function in Children and Young Adults Treated with MEK Inhibitors: A Retrospective Cohort Study. Pediatric Cardiology, 2022, , 1.	1.3	0
26	LGG-62. Weight change in pediatric patients treated with MEK inhibitors: a retrospective cohort study. Neuro-Oncology, 2022, 24, i102-i102.	1.2	0
27	LGG-23. Cardiac function in children and young adults treated with MEK inhibitors: a single institution retrospecive cohort study. Neuro-Oncology, 2022, 24, i92-i93.	1.2	Ο